Title: 2018 ACVIM Forum Research Abstract Program: Seattle, Washington, June 14 - 15, 2018 Document date: 2018_10_25
ID: 60ceejq1_273
Snippet: Intensive staining localized to cell membrane was defined as HER2 protein overexpression. The aim of this study was to assess the toxicity and efficacy of a doxorubicin/ cytarabine (DC) combination protocol in dogs with acute myeloid leukemia (AML). A cohort of 6 dogs with persistent cytopenia, and bone marrow cytology and/or core biopsy diagnosis of AML were treated with same day doxorubicin at 30 mg/m 2 or 1 mg/kg IV over 20 minutes, followed b.....
Document: Intensive staining localized to cell membrane was defined as HER2 protein overexpression. The aim of this study was to assess the toxicity and efficacy of a doxorubicin/ cytarabine (DC) combination protocol in dogs with acute myeloid leukemia (AML). A cohort of 6 dogs with persistent cytopenia, and bone marrow cytology and/or core biopsy diagnosis of AML were treated with same day doxorubicin at 30 mg/m 2 or 1 mg/kg IV over 20 minutes, followed by cytarabine at 300 mg/m 2 with constant rate IV infusion over 4 hours, every 14 days. Prednisone (2 mg/kg PO q24h) was also administered. Hematologic results, adverse effects and outcomes were assessed every 1-2 weeks during DC therapy.
Search related documents:
Co phrase search for related documents- acute myeloid leukemia and AML biopsy diagnosis: 1
- acute myeloid leukemia and biopsy diagnosis: 1
- acute myeloid leukemia and cell membrane: 1
- acute myeloid leukemia and efficacy toxicity: 1, 2
- acute myeloid leukemia and hematologic result: 1
- acute myeloid leukemia and iv infusion: 1
- acute myeloid leukemia and myeloid leukemia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- acute myeloid leukemia and study aim: 1, 2, 3
- adverse effect and constant rate: 1
- adverse effect and efficacy toxicity: 1
- adverse effect and outcome adverse effect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- adverse effect and study aim: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- AML acute myeloid leukemia and biopsy diagnosis: 1
- AML acute myeloid leukemia and iv infusion: 1
- AML acute myeloid leukemia and myeloid leukemia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- AML acute myeloid leukemia and study aim: 1, 2, 3
- AML biopsy diagnosis and biopsy diagnosis: 1
- AML biopsy diagnosis and myeloid leukemia: 1
- biopsy diagnosis and myeloid leukemia: 1
Co phrase search for related documents, hyperlinks ordered by date